News

CALL FOR PAPERS NOVEMBER 2024

IJSAR going to launch new issue Volume 05, Issue 11, November 2024; Open Access; Peer Reviewed Journal; Fast Publication. Please feel free to contact us if you have any questions or comments send email to: editor@scienceijsar.com

IMPACT FACTOR: 6.673

Submission last date: 15th November 2024

A case report on mixed connective tissue disorder and Systemic Lupus Erythematosus (SLE) with hypothyroidism

×

Error message

  • Notice: Trying to access array offset on value of type int in element_children() (line 6609 of /home1/sciensrd/public_html/scienceijsar.com/includes/common.inc).
  • Notice: Trying to access array offset on value of type int in element_children() (line 6609 of /home1/sciensrd/public_html/scienceijsar.com/includes/common.inc).
  • Deprecated function: implode(): Passing glue string after array is deprecated. Swap the parameters in drupal_get_feeds() (line 394 of /home1/sciensrd/public_html/scienceijsar.com/includes/common.inc).
Author: 
Kinjal V. Patel, Archi Desai, Romil Patel, Srinivas Nayak, S.P. and Gunosindhu Chakraborthy
Page No: 
5694-5697

Mixed connective tissue disease (MCTD) was first defined in 1972 as a condition characterized by features of systemic lupus erythematosus (SLE), systemic sclerosis (SSc), polymyositis/dermatomyositis, and rheumatoid arthritis (RA) as well as the presence of high-titer anti-U1small nuclear anti-ribonucleoprotein (anti-RNP) antibodies. A 32-year- old female housewife presented with a complaint of itching over whole body in the past 2 months, generalized weakness and Arthralgia (Joint pain) with difficulty in standing from sitting position in the last 1.5 years, generalized edema with a four-months. Particularly, in this case report systemic sclerosis, systemic lupus erythematosus and polymyositis suggests that patient is suffering from mixed connective tissue disorder. The patient was also diagnosed on the basis of clinical pattens. RA33- positive group showed major proportions of SLE- associated antibodies and low level of serum complement components. Generally, patients with MCTD are given NSAIDs to relieve symptoms and immunosuppressants to depress autoimmune reaction.

Download PDF: